ArticleBMJ open2026
Primary prevention of maternal anaemia to prevent preterm delivery and other adverse outcomes (PANDA): a protocol for a double-blind placebo-controlled randomised trial of a daily iron supplement during pregnancy.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron deficiency anaemia (IDA) affects up to 30% of all pregnant women often causing symptoms including malaise and lethargy which can significantly impact daily life and well-being. Additionally, IDA is associated with serious complications, including an increased risk of bleeding, preterm birth, small for gestational age babies and rarely, but significantly, stillbirth. The most common current management approach reactively treats IDA once it is diagnosed, usually with an oral iron preparation such as ferrous sulphate or another ferrous salt. There have been calls to investigate a policy of prevention, to discover if outcomes can be improved. We therefore designed the primary prevention of maternal anaemia to prevent preterm delivery and other adverse outcomes trial, to assess whether the prevention of IDA during pregnancy, through routine iron supplementation from early pregnancy, will reduce the risks of significant adverse clinical outcomes for women and their babies.
designRandomised, double-blind, placebo-controlled trial to evaluate the effectiveness of low-dose ferrous sulfate in the primary prevention of IDA, alongside an intervention to support medication adherence, with a parallel process evaluation to explore acceptability, fidelity and mechanisms of action.
participants11 020 women in their first trimester of pregnancy, who are not anaemic and have no contraindication to oral iron, will be recruited from maternity units.
interventionA tablet of ferrous sulfate 200 mg (65 mg of elemental iron) once daily compared with an identically matched placebo tablet, administered from recruitment in the first trimester (anytime ≤15 weeks+6 days gestation) through until 6 weeks post partum or when all of the tablets have been taken, whichever is sooner. Participants are supplied with a total of 240 tablets to cover the whole period of the study. An adherence intervention to support initiation and adherence to iron supplementation was also delivered. OUTCOMES: The primary outcome is a composite of preterm birth, small for gestational age, stillbirth and neonatal death. Secondary outcomes include development of maternal anaemia, post-partum haemorrhage, postnatal depression, breast feeding rates, quality of life scores, and in the neonate admissions to a higher level of care and early-onset infection. Long-term offspring neurodevelopmental follow-up will continue beyond this period.This study will establish the clinical and cost-effectiveness of universal oral iron supplementation in pregnancy. (ISRCTN16425597).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.